ZA200905618B - Solid forms of a Raf kinase inhibitor - Google Patents

Solid forms of a Raf kinase inhibitor

Info

Publication number
ZA200905618B
ZA200905618B ZA200905618A ZA200905618A ZA200905618B ZA 200905618 B ZA200905618 B ZA 200905618B ZA 200905618 A ZA200905618 A ZA 200905618A ZA 200905618 A ZA200905618 A ZA 200905618A ZA 200905618 B ZA200905618 B ZA 200905618B
Authority
ZA
South Africa
Prior art keywords
kinase inhibitor
solid forms
raf kinase
raf
solid
Prior art date
Application number
ZA200905618A
Other languages
English (en)
Inventor
Ahmad Hashash
Kangwen L Lin
Augustus O Okhamafe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200905618B publication Critical patent/ZA200905618B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA200905618A 2007-03-02 2009-08-13 Solid forms of a Raf kinase inhibitor ZA200905618B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90445507P 2007-03-02 2007-03-02

Publications (1)

Publication Number Publication Date
ZA200905618B true ZA200905618B (en) 2010-05-26

Family

ID=39456506

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905618A ZA200905618B (en) 2007-03-02 2009-08-13 Solid forms of a Raf kinase inhibitor

Country Status (25)

Country Link
US (1) US8324389B2 (pt)
EP (1) EP2132198A1 (pt)
JP (1) JP2010520215A (pt)
KR (1) KR20090117833A (pt)
CN (1) CN101679372A (pt)
AR (1) AR065565A1 (pt)
AU (1) AU2008251764B2 (pt)
BR (1) BRPI0808526A2 (pt)
CA (1) CA2678335A1 (pt)
CL (1) CL2008000616A1 (pt)
CO (1) CO6230987A2 (pt)
EC (1) ECSP099673A (pt)
GT (1) GT200900237A (pt)
IL (1) IL200441A0 (pt)
MA (1) MA31259B1 (pt)
MX (1) MX2009009344A (pt)
MY (1) MY148438A (pt)
NZ (1) NZ579084A (pt)
PE (1) PE20081801A1 (pt)
RU (1) RU2483064C2 (pt)
SG (1) SG179423A1 (pt)
TN (1) TN2009000356A1 (pt)
TW (1) TW200846341A (pt)
WO (1) WO2008140850A1 (pt)
ZA (1) ZA200905618B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008256922B2 (en) * 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
KR20180018800A (ko) * 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
RU2693004C1 (ru) * 2019-03-15 2019-07-01 Лейсан Фаридовна Минигулова Противоопухолевая композиция цисплатина с ингибитором 6-фосфоглюконатдегидрогеназы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
NZ535985A (en) * 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
EP2046292B1 (en) * 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
PE20080766A1 (es) 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
JP2010520215A (ja) 2010-06-10
EP2132198A1 (en) 2009-12-16
TW200846341A (en) 2008-12-01
AU2008251764B2 (en) 2012-09-13
TN2009000356A1 (en) 2010-12-31
RU2483064C2 (ru) 2013-05-27
NZ579084A (en) 2012-04-27
ECSP099673A (es) 2009-11-30
US20100209418A1 (en) 2010-08-19
WO2008140850A1 (en) 2008-11-20
AR065565A1 (es) 2009-06-17
US8324389B2 (en) 2012-12-04
AU2008251764A1 (en) 2008-11-20
MX2009009344A (es) 2009-09-11
KR20090117833A (ko) 2009-11-12
CO6230987A2 (es) 2010-12-20
MA31259B1 (fr) 2010-03-01
BRPI0808526A2 (pt) 2014-08-19
CL2008000616A1 (es) 2008-09-12
MY148438A (en) 2013-04-30
CN101679372A (zh) 2010-03-24
GT200900237A (es) 2010-06-24
IL200441A0 (en) 2010-04-29
RU2009136308A (ru) 2011-04-10
SG179423A1 (en) 2012-04-27
CA2678335A1 (en) 2008-11-20
PE20081801A1 (es) 2009-01-08

Similar Documents

Publication Publication Date Title
PL2079727T3 (pl) Inhibitory kinazy
ZA200901073B (en) Kinase inhibitor
IL213464A0 (en) Kinase inhibitor compounds
ZA201108048B (en) P38map kinase inhibitor
ZA201002543B (en) Polo-like kinase inhibitors
IL216511A0 (en) Janus kinase inhibitor compounds and methods
IL201564A0 (en) P70 s6 kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
ZA200808599B (en) 4-anilinoquinoline-3-carboxamides as CSF-1R kinase inhibitors
PL2402317T3 (pl) Inhibitor DGAT
EP2166857A4 (en) KINASE INHIBITOR COMPOUNDS
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
EP2222166A4 (en) INHIBITORS OF HETEROCYCLIC KINASES
ZA201103170B (en) A triazolothiadiazole inhibitor of c-met protein kinase
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
IL200441A0 (en) Solid forms of a raf kinase inhibitor
ZA200809874B (en) Method of inhibiting c kit kinase
EP2036893A4 (en) ABL Kinase Inhibitor
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
IL200048A (en) Solid forms of microbiocide
IL197981A0 (en) Kinase inhibitors
GB0603522D0 (en) Kinase inhibition
HK1139388A (en) Solid forms of a raf kinase inhibitor
GB0714941D0 (en) Inhibitors